EVI welcomes a new team member02 September 2015

A warm welcome is extended to EVI's new Project Manager, Oliver Schraidt who commenced duties on 1 September 2015.

MVVC/MVVC 2 collaborator receives ASTMH 2015 Annual Meeting Travel Award13 August 2015

Muhammed Afolabi (MRC Gambia) received an ASTMH 2015 Annual Meeting Travel Award that is supported in part by the Bill & Melinda Gates Foundation.

WHO-CC Vaccine Pharmacovigilance Fellowship 7th-18th September06 August 2015

The WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance is delighted to announce to you its maiden Vaccine Pharmacovigilance Fellowship Programme.  Deadline for registration is 21st August 2015.  For enquiries kindly contact us at training [at] who-pvafrica [dot] org

First Malaria vaccine with positive scientific opinion from the European Medicines Agency (EMA)24 July 2015

EVI congratulates GlaxoSmithKline and PATH Malaria Vaccine Initiative (MVI) on their resounding success on the development of MosquirixTM, also known as RTS,S, for use in children aged six weeks to 17 months. 

New EDCTP Executive Director from January 201616 July 2015

Dr. Michael Makanga will replace Professor Charles Mgone as Eecutive Director of The European & Developing Countries' Clinical Trials Partnership (EDCTP) in January 2016.

Dr. Makanga comes from a position as Head of EDCTP Africa Office in Cape Town, which he has held since 2008.

Read more

Advanced Vaccinology Course, deadline 19 October 201515 July 2015

The Institute of Tropical Medicine and International Health in Berlin is offering a two week Advanced Vaccinology Course at Campus Virchow Klinikum CVK Charité, Berlin, 11-22 January 2016.

Acess flyer for more information and application form

EVI mentioned in BMBF G7 news letter15 July 2015

A placental malaria vaccine R&D project from EVI (PRIMALVAC), funded by the Federal Ministry of Education and Research (BMBF), Germany is the subject of an article in the latest BMBF Health Research news letter.  The article provides some background information about placental malaria, and summarises the approach followed in PRIMALVAC to develop a vaccine for this particular form of malaria.  See page 10 “Malaria in der Schwangerschaft: Gefahr für Mutter und Kind".

EDUFLUVAC Workshop on immunoassay standardisation for universal flu vaccines22 June 2015

The first EDUFLUVAC workshop on immunoassay standardisation for universal flu vaccines took place on 18-19 June 2015 at the National Institute for Biological Standards and Control (NIBSC), UK.  This workshop was co-organised and co-sponsored by the National Institute of Health (NIH) / National Institute of Allergy and Infectious Diseases (NIAID), USA.

BELLEROPHON Call for process development and GMP manufacture of a vaccine candidate17 June 2015

BELLEROPHON would like to make a call for the process development and production in E. coli according to Good Manufacturing Practice (GMP) of a protein vaccine candidate to be used in toxicological and phase I studies.  The subcontracting is expected in Q4 2015.

MVVC/MVVC 2 meeting, Oxford 4 - 5 March 201517 June 2015

The annual meeting of MVVC / MVVC 2 held in Oxford in March is mentioned in the EDCTP May news letter (page 6).  Field trials of a new combination malaria vaccine, which are an integral part of the MVVC2 project, are funded by among others EDCTP.